2430 North Halsted Street
Chicago, IL 60614
United States
847 673 1700
https://www.exicuretx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 7
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Paul Kang | CEO & Director | S.O. | S.O. | 1962 |
Ms. Jiyoung Hwang | CFO & Director | S.O. | S.O. | 1976 |
Mr. Joshua Miller | Chief Accounting Officer | S.O. | S.O. | 1976 |
Mr. Bart Anderson | Senior Director of R&D | S.O. | S.O. | S.O. |
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
L’ISS Governance QualityScore de Exicure, Inc. en date du 29 avril 2024 est 10. Les scores principaux sont Audit : 10; Société : 10; Droits des actionnaires : 7; Compensation : 10.